The European In Vitro Diagnostic Medical Device Regulation (IVDR) (EU) 2017/746 came into effect on 26 May 2017 and will replace the European In Vitro Diagnostic Medical Device Directive (IVDD) 98/79/EC. A global cross-functional team at BD Biosciences has been working to implement the new regulation in a seamless and compliant manner.
We are committed to providing IVDR compliant solutions to continue delivering safe and effective IVD medical devices to serve you and your patients. We received our first IVDR product certification in December 2020 and are continuing our efforts to achieve this for other products in our clinical portfolio.
The BD Biosciences reagent portfolio planned for IVDR compliance includes in vitro diagnostic solutions for*
- Flow cytometric immunophenotyping of haematological disorders.
- Monitoring human immunodeficiency virus (HIV)–infected individuals.
- Characterising and monitoring immunodeficiency and autoimmune diseases.
- Cell enumeration of blood products for transfusion and stem cell transplantation procedures.
The BD Biosciences IVDR portfolio will also include flow cytometers and automation solutions.
*After the IVDR date of application, the products indicated on this page will be made available as IVDR compliant devices and/or as IVDD compliant devices